CY1124238T1 - Χρηση αντισωματων κατα της σκληροστινης στη θεραπεια της ατελους οστεογενεσης - Google Patents

Χρηση αντισωματων κατα της σκληροστινης στη θεραπεια της ατελους οστεογενεσης

Info

Publication number
CY1124238T1
CY1124238T1 CY20211100286T CY211100286T CY1124238T1 CY 1124238 T1 CY1124238 T1 CY 1124238T1 CY 20211100286 T CY20211100286 T CY 20211100286T CY 211100286 T CY211100286 T CY 211100286T CY 1124238 T1 CY1124238 T1 CY 1124238T1
Authority
CY
Cyprus
Prior art keywords
patient
treatment
osteogenesis
defective
osteogenesis imperfecta
Prior art date
Application number
CY20211100286T
Other languages
English (en)
Inventor
Uwe Junker
Michaela Kneissel
Anthony Kent HALL
Rena Joy EUDY
Matthew Manning RIGGS
Original Assignee
Mereo Biopharma 3 Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 3 Limited filed Critical Mereo Biopharma 3 Limited
Publication of CY1124238T1 publication Critical patent/CY1124238T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Αποκαλύπτονται μέθοδοι για θεραπεία ενός ασθενούς που πάσχει από ατελή οστεογένεση οι οποίες περιλαμβάνουν χορήγηση στον ασθενή μιας θεραπευτικώς αποτελεσματικής ποσότητας ενός αντισώματος κατά της σκληροστίνης. Αποκαλύπτονται επίσης μέθοδοι για αύξηση σχηματισμού οστού και μείωση απορρόφησης οστού σε έναν ασθενή με ατελή οστεογένεση με χορήγηση στον ασθενή μιας θεραπευτικώς αποτελεσματικής ποσότητας ενός αντισώματος κατά της σκληροστίνης. Περαιτέρω αποκαλύπτονται συνθέσεις για αύξηση σχηματισμού οστού και μείωση απορρόφησης οστού σε έναν ασθενή με ατελή οστεογένεση. Οι συνθέσεις περιλαμβάνουν μία θεραπευτικώς αποτελεσματικής ποσότητας ενός αντισώματος κατά της σκληροστίνης. Η εφεύρεση παρέχει επίσης ένα αντίσωμα κατά της σκληροστίνης για χρήση στην θεραπεία της ατελούς οστεογένεσης.
CY20211100286T 2016-12-21 2021-04-02 Χρηση αντισωματων κατα της σκληροστινης στη θεραπεια της ατελους οστεογενεσης CY1124238T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437353P 2016-12-21 2016-12-21
PCT/GB2017/053850 WO2018115880A1 (en) 2016-12-21 2017-12-21 Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Publications (1)

Publication Number Publication Date
CY1124238T1 true CY1124238T1 (el) 2022-07-22

Family

ID=60915566

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100286T CY1124238T1 (el) 2016-12-21 2021-04-02 Χρηση αντισωματων κατα της σκληροστινης στη θεραπεια της ατελους οστεογενεσης

Country Status (22)

Country Link
US (4) US20200179509A1 (el)
EP (2) EP3478719B1 (el)
JP (2) JP7050335B2 (el)
KR (2) KR20190096409A (el)
CN (2) CN117442720A (el)
AU (1) AU2017381433A1 (el)
BR (1) BR112019012731A2 (el)
CA (1) CA3047221A1 (el)
CL (1) CL2019001749A1 (el)
CY (1) CY1124238T1 (el)
DK (1) DK3478719T3 (el)
ES (1) ES2862922T3 (el)
HR (1) HRP20210207T1 (el)
HU (1) HUE053436T2 (el)
IL (1) IL267430A (el)
LT (1) LT3478719T (el)
MX (1) MX2019007161A (el)
NZ (1) NZ754676A (el)
PL (1) PL3478719T3 (el)
PT (1) PT3478719T (el)
SI (1) SI3478719T1 (el)
WO (1) WO2018115880A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
US11466079B2 (en) 2018-03-30 2022-10-11 Amgen Inc. C-terminal antibody variants
CA3104053A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Pyrazole derivatives as malt1 inhibitors
KR102472582B1 (ko) * 2020-08-20 2022-11-30 한림대학교 산학협력단 인공관절 마모편에 의한 활막염과 골용해의 진단 및 치료 방법
CA3233220A1 (en) * 2021-09-30 2023-04-06 Alastair MACKINNON Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
PT2261335T (pt) 1998-11-27 2017-09-08 Ucb Pharma Sa Composições e métodos para aumentar a mineralização óssea
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
MEP2808A (xx) 2003-06-16 2010-02-10 Celltech R & D Inc Antitijela specifična za sklerositin i metode za povećanje mineralizacije kostiju
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
US7744874B2 (en) * 2007-03-20 2010-06-29 Eli Lilly And Company Anti-sclerostin antibodies
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
WO2010100200A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
AU2011239935A1 (en) * 2010-04-16 2012-11-08 Novartis Ag Methods and compositions for improving implant osseointegration
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
MA41142A (fr) * 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
US10961305B2 (en) * 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Also Published As

Publication number Publication date
JP7050335B2 (ja) 2022-04-08
WO2018115880A1 (en) 2018-06-28
RU2019118719A3 (el) 2021-06-01
US20200179509A1 (en) 2020-06-11
KR20190096409A (ko) 2019-08-19
KR20220051269A (ko) 2022-04-26
CA3047221A1 (en) 2018-06-28
JP2022046529A (ja) 2022-03-23
CN110325548A (zh) 2019-10-11
MX2019007161A (es) 2020-02-12
CL2019001749A1 (es) 2019-12-27
CN117442720A (zh) 2024-01-26
HRP20210207T1 (hr) 2021-03-19
US20210253684A1 (en) 2021-08-19
LT3478719T (lt) 2021-04-12
AU2017381433A1 (en) 2019-07-04
PL3478719T3 (pl) 2021-10-25
EP3478719B1 (en) 2021-01-20
US20200123242A1 (en) 2020-04-23
EP3478719A1 (en) 2019-05-08
SI3478719T1 (sl) 2021-09-30
PT3478719T (pt) 2021-03-18
DK3478719T3 (da) 2021-03-01
HUE053436T2 (hu) 2021-06-28
CN110325548B (zh) 2023-11-17
ES2862922T3 (es) 2021-10-08
EP3868780A1 (en) 2021-08-25
JP2020502219A (ja) 2020-01-23
IL267430A (en) 2019-08-29
NZ754676A (en) 2023-06-30
BR112019012731A2 (pt) 2019-11-26
RU2019118719A (ru) 2021-01-22
US20230365669A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
CY1124238T1 (el) Χρηση αντισωματων κατα της σκληροστινης στη θεραπεια της ατελους οστεογενεσης
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
CY1124896T1 (el) Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων
CY1125436T1 (el) Αναστολεις dna-pk
CY1123972T1 (el) Θεραπεια συνδυασμου για καρκινο
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
CY1125025T1 (el) 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης
CY1123941T1 (el) Αντι-tfr αντισωματα και χρηση τους στη θεραπεια πολλαπλασιαστικων και φλεγμονωδων διαταραχων
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
CY1122265T1 (el) Αντισωματα εναντι ταυ και χρησεις αυτων
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
CY1124922T1 (el) Καινοτομος σταθερη φαρμακοτεχνικη μορφη για αντισωματα fxia
CY1123231T1 (el) Ενωσεις τετραϋδροπυριμιδοδιαζεπινης και τετραϋδροπυριδοδιαζεπινης για θεραπεια πονου και καταστασεων σχετικων με τον πονο
AR101740A1 (es) Terapia de combinación y composiciones
EA201591843A1 (ru) Способы лечения несовершенного остеогенеза
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
CY1123116T1 (el) Θεραπευτικη αντιμετωπιση των αυτοανοσων διαταραχων με cd154 αντισωματα
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
MX2023004333A (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
CY1118254T1 (el) Αντισωματα toy βμρ-6
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
CY1125041T1 (el) Αντισωματα anti-il-22r
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин